Top

Published in:

Open Access 01-05-2018 | Original Article

Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer

Authors: Janine T. Hidding, Carien H. G. Beurskens, Philip J. van der Wees, Wilmy C. A. M. Bos, Maria W. G. Nijhuis-van der Sanden, Hanneke W. M. van Laarhoven

Published in: Supportive Care in Cancer | Issue 5/2018

Abstract

Purposes

The purposes of this study were to investigate the incidence of lymphedema in patients with breast cancer during and after adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC), to identify predictors for development of lymphedema, and to describe consequences in daily life in relation to lymphedema.

Methods

This is a prospective study with measurements before chemotherapy (T0), during chemotherapy before cycle 2 (T1), cycle 4 (T2), and 1 month after completion of treatment (T3). Volume change was monitored using tape measurements. Lymphedema was defined as ≥ 10% volume difference. Linear mixed-effect models were estimated to analyze differences in arm volume and consequences in daily life (total score and domain scores of the Lymph-International Classification of Functioning (ICF) questionnaire) over time and to identify treatment and patient characteristics as predictors for changes in volume.

Results

Forty-eight patients completed all measurements. Volume did not change during TAC treatment. One month after treatment, volume was significantly increased compared to T0-T2, and 12 patients (25%) had developed lymphedema. Axillary lymph node dissection was associated with lymphedema (ES 2.9, 95% CI 0.02–5.7; p < 0.05). In patients with and without lymphedema, 1 month after completion (T3), the Lymph-ICF questionnaire showed significant limitations in physical function compared to T0-T2. In patients with lymphedema at T3, a significant association between volume and total score on the Lymph-ICF questionnaire on physical function and mobility activities was observed.

Conclusions

One month after treatment in 12 patients (25%), volume difference increased over 10%. Axillary lymph node dissection was predictive for development of lymphedema. All patients, but more patients with lymphedema, perceived difficulties in activities in daily life after treatment.

Available only for authorised users

DiSipio T et al (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6):500–515CrossRefPubMed

Viehoff PB et al (2015) Development of consensus International Classification of Functioning, Disability and Health (ICF) core sets for lymphedema. Lymphology 48(1):38–50PubMed

Moffat C, Doherty D, Morgan P (2006) In: Framework TL (ed) Best practice for the management of lymphoedema. International consensus. MEP. Ltd, London

Zomkowski K et al (2017) Physical symptoms and working performance in female breast cancer survivors: a systematic review. Disabil Rehabil. https://doi.org/10.1080/09638288.2017.1300950

Levangie PK, Drouin J (2009) Magnitude of late effects of breast cancer treatments on shoulder function: a systematic review. Breast Cancer Res Treat 116(1):1–15CrossRefPubMed

Hidding JT et al (2014) Treatment related impairments in arm and shoulder in patients with breast cancer: a systematic review. PLoS One. 9(5)

Hugenholtz-Wamsteker W et al (2016) The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review. Eur J Cancer Care (Engl) 25(2):269–279CrossRef

Kim M et al (2016) Identification of prognostic risk factors for transient and persistent lymphedema after multimodal treatment for breast cancer. Cancer Res Treat 48(4):1330–1337CrossRefPubMedPubMedCentral

Kilbreath SL et al (2016) Risk factors for lymphoedema in women with breast cancer: a large prospective cohort. Breast 28:29–36CrossRefPubMed

10.

Yang EJ et al (2016) Use of a prospective surveillance model to prevent breast cancer treatment-related lymphedema: a single-center experience. Breast Cancer Res Treat 160(2):269–276CrossRefPubMedPubMedCentral

11.

Swaroop MN et al (2015) Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort. Breast Cancer Res Treat 151(2):393–403PubMedPubMedCentral

12.

Cariati M et al (2015) Adjuvant taxanes and the development of breast cancer-related arm lymphoedema. Br J Surg 102(9):1071–1078CrossRefPubMed

13.

Lee MJ et al (2014) Lymphedema following taxane-based chemotherapy in women with early breast cancer. Lymphat Res Biol 12(4):282–288CrossRefPubMed

14.

Jung SY et al (2014) Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients. Breast Cancer Res Treat 148(1):91–98CrossRefPubMed

15.

http://richtlijnendatabase.nl/richtlijn/breast_cancer/breast_cancer.html. 2012, IKNL and KiMS

16.

Mackey JR et al (2013) Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14(1):72–80CrossRefPubMed

17.

Stout NL et al (2011) Segmental limb volume change as a predictor of the onset of lymphedema in women with early breast cancer. PM R 3(12):1098–1105CrossRefPubMed

18.

Hidding JT et al (2016) Measurement properties of instruments for measuring of lymphedema: a systematic review. Phys Ther 96(12):1965–1981CrossRefPubMed

19.

Devoogdt N et al (2011) Lymphoedema Functioning, Disability and Health questionnaire (Lymph-ICF): reliability and validity. Phys Ther 91(6):944–957CrossRefPubMed

20.

Fleiss JL, Levin B, Paik MC (2003) Statistical methods for rates and proportions, 3rd edn. Wiley, New York

21.

Bromham N et al (2017) Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev 1:Cd004561PubMed

22.

Donker M et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303–1310CrossRefPubMedPubMedCentral

23.

Ashikaga T et al (2010) Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 102(2):111–118CrossRefPubMedPubMedCentral

24.

Hayes S, Cornish B, Newman B (2005) Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up. Breast Cancer Res Treat 89(3):221–226CrossRefPubMed

25.

Dylke ES et al (2016) Diagnosis of upper limb lymphedema: development of an evidence-based approach. Acta Oncol 55(12):1477–1483CrossRefPubMed

26.

Czerniec SA et al (2010) Assessment of breast cancer-related arm lymphedema—comparison of physical measurement methods and self-report. Cancer Investig 28(1):54–62CrossRef

27.

Segal R et al (2017) Exercise for people with cancer: a clinical practice guideline. Curr Oncol 24(1):40–46CrossRefPubMedPubMedCentral

28.

Andersen KG et al (2012) Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide. Acta Oncol 51(8):1036–1044CrossRefPubMed

29.

Kopec JA et al (2013) Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32. J Support Oncol 11(1):22–30PubMedPubMedCentral

30.

Testa A, Iannace C, Di Libero L (2014) Strengths of early physical rehabilitation programs in surgical breast cancer patients: results of a randomized controlled study. Eur J Phys Rehabil Med 50(3):275–284PubMed

31.

van Waart H et al (2015) Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial. J Clin Oncol 33(17):1918–1927CrossRefPubMed

32.

Norman SA et al (2009) Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol 27(3):390–397CrossRefPubMedPubMedCentral

33.

Armer JM et al (2003) Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res 52(6):370–379CrossRefPubMed

34.

Furmaniak Anna CA (2016) Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005001.pub3

35.

Harrington S et al (2014) Patient-reported upper extremity outcome measures used in breast cancer survivors: a systematic review. Arch Phys Med Rehabil 95(1):153–162CrossRefPubMed

36.

Hickey BE, Francis DP, and Lehman M (2013) Sequencing of chemotherapy and radiotherapy for early breast cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005212.pub3

37.

Goker M et al (2013) Systematic review of breast cancer related lymphoedema: making a balanced decision to perform an axillary clearance. Facts Views Vis Obgyn 5(2):106–115PubMedPubMedCentral

38.

McNeely ML et al (2004) The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast Cancer Res Treat 86(2):95–106CrossRefPubMed

39.

Springer BA et al (2010) Pre-operative assessment enables early diagnosis and recovery of shoulder function in patients with breast cancer. Breast Cancer Res Treat 120(1):135–147CrossRefPubMedPubMedCentral

40.

Sun F et al (2016) The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema. Breast Cancer Res Treat 157(2):229–240CrossRefPubMed

41.

Ancukiewicz M et al (2011) Standardized method for quantification of developing lymphedema in patients treated for breast cancer. Int J Radiat Oncol Biol Phys 79(5):1436–1443CrossRefPubMed

42.

Miller CL et al (2013) A novel, validated method to quantify breast cancer-related lymphedema (BCRL) following bilateral breast surgery. Lymphology 46(2):64–74PubMed

Title: Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer
Authors: Janine T. Hidding
Carien H. G. Beurskens
Philip J. van der Wees
Wilmy C. A. M. Bos
Maria W. G. Nijhuis-van der Sanden
Hanneke W. M. van Laarhoven
Publication date: 01-05-2018
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 5/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-017-3907-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purposes

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2018

Racial differences in symptom management experiences during breast cancer treatment

Antimicrobial therapy in palliative care: an overview

The impact of palliative care training for oncologists and integrative palliative service in a public-funded hospital cluster—a retrospective cohort study

Accuracy of cystatin C for the detection of abnormal renal function in children undergoing chemotherapy for malignancy: a systematic review using individual patient data

The mediating role of spirituality (meaning, peace, faith) between psychological distress and mental adjustment in cancer patients

Patient-clinician communication among patients with stage I lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer